Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

One of the major complications of allogeneic bone marrow transplantation is graft-versus-host disease. This can be avoided by removing the mature T cells from the marrow, most conveniently by the use of monoclonal antibodies. However, T cell purging results in an increased tendency for the recipient to reject the donor marrow. We have developed monoclonal antibodies to L3/T4 and Lyt-2 that specifically deplete functional T cell subsets in mice. We demonstrate that such reagents can be used to control both graft-versus-host disease and marrow rejection in mouse models of bone marrow transplantation across one-haplotype or two-haplotype major histocompatibility differences. Such strategies to abrogate host resistance, by administration of anti-T-cell monoclonal antibodies to the recipient, may complement marrow T cell purging for human allogeneic bone marrow transplantation.


Journal article



Publication Date





239 - 247


Animals, Antibodies, Monoclonal, Bone Marrow Transplantation, Chimera, Graft Rejection, Graft vs Host Disease, Immunocompetence, Isoantibodies, Lymphocyte Depletion, Major Histocompatibility Complex, Mice, Mice, Inbred Strains, Rats, Rats, Inbred Strains, T-Lymphocytes, Transplantation, Homologous